PGT-A Billing: CPT Codes, Authorization, and Denial Prevention

PGT-A (preimplantation genetic testing for aneuploidy) adds a significant layer of billing complexity to an IVF cycle. Unlike a standard retrieval-and-transfer cycle, PGT-A involves embryo biopsy codes from the 89xxx series, genetic analysis codes billed by a separate reference laboratory, and a frozen embryo transfer cycle that requires its own prior authorization. Each of these three billing phases has distinct code requirements, documentation standards, and denial patterns. A billing team that handles each phase correctly — and coordinates across all three — consistently captures revenue that less specialized teams lose to preventable denials.

What PGT-A Tests For — and Why Billing Staff Need to Know

PGT-A screens embryos for chromosomal aneuploidy — the presence of an abnormal number of chromosomes — before transfer. Aneuploidy is the leading cause of IVF failure and early pregnancy loss, particularly in patients over 35. For billing purposes, the clinical indication matters in two ways: it determines the correct ICD-10 code (advanced maternal age, recurrent pregnancy loss, and prior failed IVF cycles map to different codes and carry different medical necessity weight), and it directly supports the documentation required for prior authorization in plans that cover PGT. Billing staff who understand the clinical rationale for PGT-A can better identify when the authorization documentation is incomplete or when the ICD-10 code selection does not align with the chart.

The Full PGT-A Code Set: Clinic vs. Genetics Lab

PGT-A billing involves two distinct billing entities: the IVF clinic (which performs the biopsy and the subsequent FET) and the third-party genetics reference laboratory (which performs the chromosomal analysis). The code sets are complementary and non-overlapping when applied correctly. The most common and costly billing error is when the clinic submits genetic analysis codes that belong exclusively on the genetics lab's claim.

ICD-10 Code Selection for PGT-A Claims

The ICD-10 codes submitted with PGT-A claims must reflect the documented clinical indication for aneuploidy testing. Submitting a non-specific infertility code without a specific clinical reason for PGT-A creates a medical necessity mismatch that triggers payer review. Always use the most specific code the clinical documentation supports — the chart must back up the code at both the procedure level and the authorization level.

Prior Authorization Requirements for PGT-A

PGT-A prior authorization is more documentation-intensive than a standard IVF authorization and frequently requires two or three separate authorization tracks. Many payers that cover PGT-A require documentation of specific medical necessity criteria beyond a general infertility diagnosis — and the authorization must explicitly list every CPT code that will appear on the clinic's claim. Submitting an incomplete authorization is the most common reason PGT-A claims deny on first pass.

• Specify the PGT type explicitly: PGT-A (aneuploidy) must be designated in the authorization request. Some payers have distinct authorization pathways for PGT-A versus PGT-M or PGT-SR — a generic "PGT" request may result in approval for the wrong testing type or an incomplete approval that covers only part of the cycle.
• Document all clinical indications: advanced maternal age, prior failed IVF cycles, recurrent pregnancy loss, or prior chromosomally abnormal pregnancy — include every documented indicator, not just the primary diagnosis code.
• Include the genetics reference laboratory name and NPI: some payers require the analysis to be performed at an in-network genetics lab. An authorization issued without confirming lab network status may not cover the analysis codes at adjudication.
• List biopsy CPT codes explicitly: 89290 or 89291 must be listed in the authorization. IVF retrieval authorization (58970) does not automatically extend to biopsy codes — they require separate listing in the request.
• Obtain a separate FET authorization: the biopsy authorization does not cover the subsequent FET cycle. Every FET following PGT-A requires its own authorization covering 89352, 58976, and endometrial monitoring codes.
• Confirm authorization expiration dates before each cycle start: if the stimulation cycle is cancelled and restarted, the biopsy authorization may have expired. Reissue before proceeding rather than relying on a prior approval that has aged out.

Top PGT-A Denial Reasons and How to Prevent Them

• Incorrect biopsy code: billing 89290 when 89291 is correct (5 or more embryos biopsied), or billing 89291 when fewer than 5 were biopsied. Code mismatches create an audit discrepancy with the embryology lab record and are a common first-pass denial trigger.
• Clinic bills genetic analysis codes: 81228 or 81229 appearing on the IVF clinic's claim conflicts with the genetics lab's concurrent submission of the same codes. The result is a post-payment refund recovery demand that can cover a year or more of paid claims.
• Authorization does not list biopsy CPT codes: IVF retrieval authorization (58970) does not extend to PGT-A biopsy codes. The authorization must explicitly include 89290 or 89291 or those codes will deny regardless of the cycle being otherwise approved.
• FET submitted under the IVF retrieval or biopsy authorization: each FET is a distinct clinical cycle requiring standalone prior authorization. Submitting a FET claim under an expired or mismatched retrieval authorization results in denial with a weak appeal position.
• Out-of-network genetics lab: when the payer requires in-network genetics lab participation and the chosen lab has no contract, the analysis claim either denies entirely or is subject to out-of-network patient cost-sharing that was not disclosed before the cycle began.
• ICD-10 code mismatch between authorization and claim: if the diagnosis codes on the claim differ from those used in the authorization — even when the claim code is technically more specific — many payers trigger a mismatch denial. Match the claim diagnosis codes to the authorization codes precisely.
• Missing S codes for mandate-state fertility benefit claims: in states where the fertility benefit manager requires S codes for cycle tracking, omitting them causes a claim rejection requiring full resubmission rather than an appeal.

The FET Cycle That Always Follows PGT-A

Because PGT-A results take 5 to 14 days from biopsy, all PGT-A cycles are freeze-all cycles — every biopsied embryo is vitrified before analysis is complete. The billing chain for every PGT-A cycle therefore extends to a second claim event: the FET in which a euploid embryo is transferred. The FET uses the standard code set — 89352 for the embryo thaw and 58976 for the transfer — along with endometrial monitoring codes (76830 for ultrasound, 82670 for estradiol, 84144 for progesterone) billed on each date of service during endometrial preparation. The diagnosis on the FET claim should reference the same infertility etiology documented for the retrieval cycle. The PGT-A result — euploid, aneuploid, or mosaic — is a clinical laboratory classification that belongs in the procedure note as narrative context, not as a claim-level ICD-10 diagnosis code.

Documentation Requirements for PGT-A Audit Defense

• Embryology lab record: document total embryo count biopsied, biopsy day (Day 5, 6, or 7), biopsy technique (trophectoderm biopsy), and the number of embryos vitrified after biopsy. This record must support the code selected (89290 vs. 89291) and the cryopreservation code (89258).
• PGT-A result report from the genetics lab: retain the final result report for each embryo tested as part of the clinical record. The report supports both the clinical decision to transfer a specific embryo and the medical necessity of the subsequent FET.
• Authorization match log: for each date of service, confirm that the CPT codes submitted match an active authorization. The authorization number must appear on every claim line that requires one, exactly as issued.
• Written billing coordination agreement with the genetics lab: a formal agreement specifying which entity bills which CPT codes provides the documentation needed to defend against any post-pay audit alleging duplicate billing.
• FET procedure note connecting PGT-A to transfer: the FET note should document that the embryo transferred was biopsied under PGT-A and resulted as euploid. This narrative directly supports the medical necessity of the transfer following genetic testing.
• Patient disclosure documentation: record that the patient was informed the genetics lab will bill separately, may have different network participation, and may generate different patient cost-sharing than the IVF clinic.

PGT-A billing is one of the highest-risk areas in fertility revenue cycle management — not because the codes are obscure, but because the billing chain spans multiple encounters, multiple billing entities, and a prior authorization structure that commercial plans handle inconsistently. Practices that build explicit coordination protocols with their genetics lab partners, obtain separate authorizations for each billing phase at the start of every cycle, and train billing staff to recognize exactly where clinic billing responsibility ends will consistently outperform those that treat PGT-A as a variation on standard IVF billing.